Double Marker Study

Overview

The Double Marker Study, also known as the Combined First Trimester Screening, is a prenatal screening test used to assess the risk of chromosomal abnormalities in an unborn baby. It is performed between the 9th and 13th weeks of pregnancy and combines biochemical markers in the mother’s blood with ultrasound findings to calculate risk levels.

This test helps detect three major chromosomal syndromes:

1. Down Syndrome (Trisomy 21)
2. Edward’s Syndrome (Trisomy 18)
3. Patau’s Syndrome (Trisomy 13)

The test measures Free Beta hCG and PAPP-A (Pregnancy-Associated Plasma Protein A), and combines these results with NT (Nuchal Translucency) and CRL (Crown-Rump Length) obtained from a specialized ultrasound. The Double Marker Study does not diagnose abnormalities—it only provides a risk proportion. High-risk results may require confirmation through amniocentesis or chorionic villous sampling, followed by genetic counseling.

Symptoms

The test itself does not screen for physical symptoms in the mother; rather, it screens for potential developmental problems in the baby. The abnormalities indicated by this test are associated with specific fetal symptoms described in the PDF.

Symptoms Related to Trisomy 13 (Patau Syndrome):

1. Cleft palate
2. Extra fingers or toes
3. Low muscle tone
4. Small head
5. Possible severe defects in internal organs

Symptoms Related to Trisomy 18 (Edward’s Syndrome):

1. Craniofacial malformations
2. Abnormal hands and feet
3. Skeletal malformations
4. Congenital heart defects
5. Cryptorchidism
6. Feeding difficulty
7. Under-developed lungs
8. Joint and bone abnormalities
9. Hearing loss
10. Cleft lip
11. Eye defects

Symptoms Related to Down Syndrome (Trisomy 21):

1. Characteristic facial features
2. Learning difficulties
3. Birth defects
4. Vision and hearing problems
5. Possible heart abnormalities

These symptoms highlight why early screening is essential for pregnancy planning and management.

Causes

According to the PDF, chromosomal abnormalities detected by the Double Marker Study arise from genetic issues leading to abnormal fetal development.

Primary Causes Detected by the Test:

1. Trisomy 13 (Patau’s Syndrome): Caused by an extra chromosome 13, leading to severe structural and organ defects.
2. Trisomy 18 (Edward’s Syndrome): Caused by an extra chromosome 18, resulting in multiple malformations and developmental challenges.
3. Trisomy 21 (Down Syndrome): Caused by an extra chromosome 21, the most common trisomy associated with cognitive and physical challenges.

Biochemical Causes Indicated by Markers:

1. Low PAPP-A: Associated with abnormal placentation, poor fetal growth, pregnancy-induced hypertension, preeclampsia, and possible stillbirth.
2. Abnormal Free Beta hCG levels: Indicate variations in trophoblastic function and increased likelihood of chromosomal abnormalities.

Technical Causes (Affecting Interpretation):

1. Incorrect gestational age
2. Inaccurate NT or CRL measurements
3. Missing ultrasound reports
4. Incomplete patient information (age, weight, LMP)

Risk Factors

The PDF identifies several factors that may increase the likelihood of abnormal Double Marker results or influence risk calculation.

Maternal Risk Factors:

1. Advanced maternal age
2. History of chromosomal abnormalities in previous pregnancies
3. Medical conditions such as diabetes
4. Medication use, including hormonal treatments (e.g., hCG injections)
5. IVF pregnancies, where donor age affects the calculation
6. Inaccurate or incomplete medical history

Test-Related Risk Factors:

1. Errors in ultrasound measurements (NT, CRL)
2. Incorrect gestational age interpretation
3. Low PAPP-A levels in first trimester
4. High Free Beta hCG MoM values
5. Calculation biases due to incorrect patient data, such as weight or date of birth

Syndrome-Specific Risk Patterns (MoM Values):

1. High Free Beta hCG MoM + Low PAPP-A MoM = Increased risk of Down Syndrome
2. Opposite pattern = Decreased risk

These factors emphasize the need for precise data entry and quality imaging.

Prevention

Prevention in the context of the Double Marker Study focuses on accurate testing, proper data collection, and early pregnancy monitoring, as highlighted in the PDF.

Clinical Prevention Measures:

1. Conduct the test strictly between 9–13 weeks for reliable results.
2. Provide complete patient information, including weight, height, LMP, and medical history.
3. Ensure accurate NT and CRL ultrasound measurements by a trained fetal medicine expert.
4. Discuss the purpose, benefits, and implications of the test in detail with the patient.
5. Recommend further diagnostic tests (CVS or amniocentesis) when risk is high.
6. Offer genetic counseling to help families understand the results.

Sample Collection Prevention:

1. Collect 3 mL blood in a plain red-capped tube.
2. Separate serum early and send it with:
   1. Patient DOB
   2. Weight
   3. LMP
   4. Ultrasound report containing fetal age & NT measurement

Interpretation Prevention:

1. Use standard software such as SsdwLab to generate MoM values.
2. Always combine biochemical markers, maternal information, and ultrasound data for complete risk assessment.
3. Remember that this is a screening, not a diagnostic test.